AU2002212733A1 - Paramyxovirus vector for gene transfer to the cardiovascular system - Google Patents

Paramyxovirus vector for gene transfer to the cardiovascular system

Info

Publication number
AU2002212733A1
AU2002212733A1 AU2002212733A AU1273302A AU2002212733A1 AU 2002212733 A1 AU2002212733 A1 AU 2002212733A1 AU 2002212733 A AU2002212733 A AU 2002212733A AU 1273302 A AU1273302 A AU 1273302A AU 2002212733 A1 AU2002212733 A1 AU 2002212733A1
Authority
AU
Australia
Prior art keywords
cardiovascular system
vector
gene transfer
paramyxovirus vector
paramyxovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002212733A
Inventor
Eric Wfw Alton
Stefano Ferrari
Duncan M. Geddes
Uta Griesenbach
Mamoru Hasegawa
Xiaogang Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
Original Assignee
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc
Publication of AU2002212733A1 publication Critical patent/AU2002212733A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

The present invention provides a paramyxovirus vector for gene transfer to the cardiovascular system and uses thereof. The invention enables the efficient transfer of a foreign gene product to the cardiovascular system by use of the paramyxovirus vector. Products of genes introduced by intranasal or intramuscular administration of the paramyxovirus vector were detected in blood at high levels. The administration of a vector for the expression of the anti-inflammatory cytokine IL-10 inhibited collagen deposition in lung of pulmonary fibrosis model animal. Thus, the vector of the present invention is suitable for gene transfer to the cardiovascular system.
AU2002212733A 2000-11-08 2001-11-08 Paramyxovirus vector for gene transfer to the cardiovascular system Abandoned AU2002212733A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-339942 2000-11-08
JP2000339942A JP2002142770A (en) 2000-11-08 2000-11-08 Paramyxovirus vector for transporting gene to circulatory system
PCT/JP2001/009786 WO2002038726A2 (en) 2000-11-08 2001-11-08 Paramyxovirus vector for gene transfer to the cardiovascular system

Publications (1)

Publication Number Publication Date
AU2002212733A1 true AU2002212733A1 (en) 2002-05-21

Family

ID=18814933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002212733A Abandoned AU2002212733A1 (en) 2000-11-08 2001-11-08 Paramyxovirus vector for gene transfer to the cardiovascular system

Country Status (13)

Country Link
US (1) US20040101965A1 (en)
EP (2) EP1662003A3 (en)
JP (1) JP2002142770A (en)
KR (1) KR100852078B1 (en)
CN (1) CN1555417B (en)
AT (1) ATE323149T1 (en)
AU (1) AU2002212733A1 (en)
CA (1) CA2428073C (en)
DE (1) DE60118771T2 (en)
DK (1) DK1334174T3 (en)
ES (1) ES2260301T3 (en)
HK (1) HK1070100A1 (en)
WO (1) WO2002038726A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
WO2001018223A1 (en) 1999-09-06 2001-03-15 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
JPWO2001072340A1 (en) 2000-03-30 2004-01-08 株式会社ディナベック研究所 AIDS virus vaccine using Sendai virus vector
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
EP1297852A4 (en) * 2000-06-27 2004-12-29 Dnavec Research Inc Virus vector for introducing gene into renal cells
CN1526014A (en) * 2000-10-06 2004-09-01 ��ʽ���������о��� Paramyxovirus vectors for introducing foreign genes into skeletal muscle
WO2002042481A1 (en) 2000-11-27 2002-05-30 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
KR20040104673A (en) * 2002-04-30 2004-12-10 가부시키가이샤 디나벡크 겐큐쇼 Drug- or gene-carrier composition having lowered hemagglutinin activity
EP1548101A4 (en) * 2002-09-04 2006-05-10 Dnavec Research Inc Methods of producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope using neuraminidase derived from gram-positive bacteria
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
US20070105208A1 (en) * 2003-06-30 2007-05-10 Jun You Minus strand rna virus vector carrying gene modified in high mutation region
KR20060129013A (en) * 2004-01-13 2006-12-14 가부시키가이샤 디나벡크 겐큐쇼 Gene therapy for tumor using minus-strand rna virus vector encoding immunostimulating cytokine
WO2005071085A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Process for producing virus vector
CN1957084A (en) * 2004-03-23 2007-05-02 株式会社载体研究所 Bone marrow-relevant cell participating the maintenance and/or repair of tissue
US20090170798A1 (en) * 2005-04-20 2009-07-02 Japan As Represented By President Of National Center For Geriatrics And Gerontology Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
CA2612168A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Methods for producing antibodies
JPWO2007049752A1 (en) * 2005-10-28 2009-04-30 ディナベック株式会社 Gene transfer into airway epithelial stem cells using lentiviral vectors pseudotyped with RNA or DNA virus spike proteins
KR20080094910A (en) * 2006-01-17 2008-10-27 디나벡크 가부시키가이샤 Novel protein expression system
CN106913865A (en) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (en) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) * 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107106655A (en) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2995120A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
JPS6147186A (en) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst Method of purifying influenza virus
JPS6147185A (en) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst Method of purifying japanese b encephalitis virus
JPS6147187A (en) 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst Method of purifying rabies virus
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US6562596B1 (en) * 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5635380A (en) * 1994-01-18 1997-06-03 Vanderbilt University Enhancement of nucleic acid transfer by coupling virus to nucleic acid via lipids
US5639661A (en) * 1994-03-23 1997-06-17 The University Of Iowa Research Foundation Genes and proteins for treating cystic fibrosis
ATE257175T1 (en) * 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr RECOMBINANT INFECTIOUS NON-SEGMENTED, NEGATIVE STRAND RNA VIRUS
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
DK0864645T3 (en) * 1995-10-31 2005-10-24 Dnavec Research Inc Negative stranded RNA virus vector with autonomic replication activity
KR100525687B1 (en) * 1995-11-01 2005-11-25 가부시끼가이샤 디나벡 겡뀨쇼 Recombinant Sendai Virus
WO1997032010A1 (en) 1996-02-29 1997-09-04 Takara Shuzo Co., Ltd. Method of purifying and removing viruses
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
DE69739351D1 (en) * 1996-12-16 2009-05-20 Eisai R&D Man Co Ltd DNA construct comprising a drug resistance gene and a foreign gene
CA2205076A1 (en) * 1997-05-14 1998-11-14 Jim Hu Episomal expression cassettes for gene therapy
FR2766706B1 (en) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa STABLE PARTICULATE COMPLEXES OF NEUTRAL OR NEGATIVE GLOBAL LOAD OF MULTILAMELLAR STRUCTURE COMPOSED OF AT LEAST ONE BIOLOGICALLY ACTIVE GLOBALLY ANIONIC SUBSTANCE AND A CATIONIC COMPONENT, THEIR PREPARATION AND USE
US5962274A (en) * 1998-03-13 1999-10-05 Wake Forest University Viral vector directed to predetermined target cells
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
US6514728B1 (en) * 1998-11-09 2003-02-04 Nippon Biocaptal Limited Process for preparation of cytokines using Sendai virus expression system
JP2000201689A (en) * 1998-11-09 2000-07-25 Nippon Bio Capital Limited:Kk Production of cytokine using sendai virus expression system
JP2000253876A (en) * 1999-03-08 2000-09-19 Dnavec Research Inc Vaccine using sendai virus vector, and vaccine protein
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20030022376A1 (en) * 1999-05-18 2003-01-30 Kaio Kitazato Paramyxovirus-derived RNP
AU4614600A (en) 1999-05-18 2000-12-05 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene
DE60039292D1 (en) 1999-05-18 2008-08-07 Dnavec Research Inc RIBONUCLEOPROTEIN COMPLEX FROM PARAMYXOVIRUS
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
WO2001018223A1 (en) * 1999-09-06 2001-03-15 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
KR100774796B1 (en) * 2000-01-19 2007-11-07 가부시키가이샤 디나벡크 겐큐쇼 Use of ?aramyxovirus vector in gene transfer into blood vessel
JPWO2001072340A1 (en) * 2000-03-30 2004-01-08 株式会社ディナベック研究所 AIDS virus vaccine using Sendai virus vector
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CA2413995C (en) * 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
EP1297852A4 (en) * 2000-06-27 2004-12-29 Dnavec Research Inc Virus vector for introducing gene into renal cells
CN1526014A (en) * 2000-10-06 2004-09-01 ��ʽ���������о��� Paramyxovirus vectors for introducing foreign genes into skeletal muscle
WO2002042481A1 (en) * 2000-11-27 2002-05-30 Dnavec Research Inc. Paramyxovirus vector encoding angiogenesis gene and utilization thereof
AU2003275581A1 (en) * 2002-10-24 2004-05-13 Dnavec Research Inc. Method of transferring gene into t cells
US20060216824A1 (en) * 2003-01-31 2006-09-28 Tsuyoshi Tokusumi Paramyxovirus vector encoding ribozyme and utilization thereof
US20070105208A1 (en) * 2003-06-30 2007-05-10 Jun You Minus strand rna virus vector carrying gene modified in high mutation region
CN1902312B (en) * 2003-11-04 2011-02-23 株式会社载体研究所 Method of constructing transgenic dendritic cell
KR20060129013A (en) * 2004-01-13 2006-12-14 가부시키가이샤 디나벡크 겐큐쇼 Gene therapy for tumor using minus-strand rna virus vector encoding immunostimulating cytokine
CN1957084A (en) * 2004-03-23 2007-05-02 株式会社载体研究所 Bone marrow-relevant cell participating the maintenance and/or repair of tissue
US20090170798A1 (en) * 2005-04-20 2009-07-02 Japan As Represented By President Of National Center For Geriatrics And Gerontology Highly safe intranasally administrable gene vaccines for treating alzheimer's disease

Also Published As

Publication number Publication date
EP1662003A2 (en) 2006-05-31
EP1662003A3 (en) 2006-06-14
CN1555417A (en) 2004-12-15
US20040101965A1 (en) 2004-05-27
DE60118771T2 (en) 2007-04-12
JP2002142770A (en) 2002-05-21
CN1555417B (en) 2010-04-28
KR20030074617A (en) 2003-09-19
DK1334174T3 (en) 2006-06-26
CA2428073A1 (en) 2002-05-16
KR100852078B1 (en) 2008-08-13
WO2002038726A3 (en) 2003-03-20
ES2260301T3 (en) 2006-11-01
HK1070100A1 (en) 2005-06-10
EP1334174B1 (en) 2006-04-12
DE60118771D1 (en) 2006-05-24
EP1334174A2 (en) 2003-08-13
WO2002038726A2 (en) 2002-05-16
CA2428073C (en) 2012-01-10
ATE323149T1 (en) 2006-04-15

Similar Documents

Publication Publication Date Title
HK1070100A1 (en) Paramyxovirus vector for gene transfer to the cardiovascular system
NZ312332A (en) Recombinational cloning using engineered recombination sites
WO2001038514A3 (en) Methods, media and apparatus for the introduction of molecules into plant cells and bacteria using aerosol beams
HK1034287A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
DE69834908D1 (en) METHOD FOR INCREASING THE EXPRESSION OF ENDOGENIC OR EXOGENOUS GENE PRODUCTS IN PLANTS
WO1999018228A3 (en) Method for microbial production of amino acids of the aspartate and/or glutamate family and agents which can be used in said method
WO2003014347A3 (en) Plant seed specific promoters
IL188362A0 (en) Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
AU2001264166A1 (en) Vector constructs
AU2003241413A1 (en) Method and system of providing a product in a refillable container
CA2153254A1 (en) Cloning of enterokinase and method of use
EP0873049A4 (en)
WO2004005221A3 (en) Benzoate- and anthranilate-inducible promoters
AU2002343094A1 (en) Use of ppar activators for the treatment of pulmonary fibrosis
HUP9701387A2 (en) Seasoning sauce
ES8608581A1 (en) Synthetic genes for bovine parainfluenza virus
NO975921D0 (en) Preparation of bicyclohexane derivatives
WO2003029274A3 (en) Paramyxoviruses as gene transfer vectors to lung cells
WO2002002766A3 (en) Natural promoters for gene expression and metabolic monitoring in bacillus species
IL133032A0 (en) Gene delivery vectors provided with a tissue tropism for smooth muscle cells and/or endothelial cells
CA2102043A1 (en) Mutant aox2 promoter, vector carrying same, transformant, and production of heterologous protein
DE69226975T2 (en) Process for the preparation of alpha-acetolactic acid
AU2001292310A1 (en) Method of regulating the activity of expression product of gene transferred intoliving body
WO2000049166A3 (en) Production of helper dependent adenovirus vectors based on use of endonucleases
BR0100816A (en) Bacterium belonging to the genus methilophilus, and, process to produce l-phenylalanine